Association between TKI-induce high blood pressure and outcomes in patients with kidney cancer

In this retrospective study published in Cancer Reports the association between TKI-induced high blood pressure (hypertension) and treatment outcomes was reported. Fifty-two (52) patients with metastatic renal cell carcinoma (RCC) treated with first-line sunitinib, pazopanib, sorafenib, axitinib, or cabozantinib were examined for any association between TKI-induced hypertension and treatment outcomes. The study found that patients […]

read more

Safety and efficacy of apatinib for metastatic kidney cancer

A recent study coming out of China has identified a new oral tyrosine kinase inhibitor (TKI) with promising safety and efficacy for metastatic renal cell carcinoma (RCC). Anti-angiogenic treatments, such as the TKIs sunitinib, pazopanib and axitinib, play an important role in the treatment of metastatic RCC. A new TKI called apatinib targets the vascular […]

read more

Biomarkers and outcomes for pembrolizumab/axitinib for kidney cancer

In this phase 1b study, he researchers were looking for a relationship between biomarkers found in the blood and outcomes following treatment with a combination pembrolizumab plus axitinib for advanced renal cell carcinoma (RCC). They found that high levels of a T cell protein receptor called CD8 in the kidney tumour at baseline were associated […]

read more

Circulating tumour DNA as a potential prognostic biomarker for immunotherapy

A study published in Nature Cancer showed that blood levels of DNA from solid tumours (circulating tumour DNA or ctDNA) were associated with the prognosis of cancer patients with different types of  tumours who had been treated with pembrolizumab. The study included 94 patients with various solid tumours who were treated with pembrolizumab. ctDNA levels varied […]

read more

Safety and efficacy of nivolumab for non-clear cell kidney cancer

Nivolumab alone and in combination with ipilimumab is used for the treatment of patients with metastatic renal cell carcinoma (RCC). However, most patients with non-clear cell RCC are excluded from clinical trials, and there is limited data on the effectiveness of nivolumab for the treatment of these patients. This phase IIIb/IV CheckMate 374 study was conducted to look at […]

read more

Comparison of first-line immunotherapy combinations for metastatic kidney cancer

This meta-analysis of first-line immunotherapy trials was published in the journal Cancers last month. The analysis compares the three active first-line treatment combinations for metastatic renal cell carcinoma (RCC) and provides guidance in the selection of treatment for previously untreated patients. Three combination treatments were compared; pembrolizumab plus axitinib, avelumab plus axitinib and nivolumab plus […]

read more

Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors

This retrospective study published in the Journal of Clinical Oncology looked at the response rates and progression-free survival of metastatic renal cell carcinoma (RCC) patients treated with a combination of ipilimumab plus nivolumab after previous treatment with an immune checkpoint inhibitor. Forty-five patients with metastatic RCC who had already been treated with an immune checkpoint […]

read more

Sunitinib re-challenge in patients with metastatic kidney cancer

A study published in Clinical Genitourinary Cancer looks at the treatment of patients with metastatic RCC with sunitinib after they have already been treated with sunitinib and have stopped responding. Sunitinib is the standard of care for patients with metastatic RCC. However, nearly all patients will eventually stop responding to treatment with sunitinib and develop […]

read more

Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab

In a paper published in Clinical Genitourinary Cancer the link between immune-related adverse events and clinical outcomes in patients with metastatic renal cell carcinoma (RCC) was investigated. One hundred and sixty seven (167) patients were included in the study. Of these, 46% had an immune-related adverse event, of which 8.9% were severe or life-threatening. However, […]

read more

Bone metastases are associated with poor prognosis in papillary kidney cancer

A recent retrospective study looked at the data from 49 patients with metastatic papillary renal cell carcinoma (RCC) who were taking targeted therapy (VEGF-TKIs). The study showed that patients on targeted therapy and with bone metastases from papillary RCC have worse progression-free survival and overall survival than patients without bone metastasis. Patients with papillary RCC […]

read more
Showing 1 to 10 of 71 results
  TOP